Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REBEL: Radiation Followed by Bispecific Antibody Therapy for R/R DLBCL
NCT07528352Phase 1Recruiting
- Sponsor
- University of Utah
- Start
- Jun 2026
- Primary completion
- Jun 2030
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of epcoritamab and glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by University of Utah. Primary endpoint: Rate of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome at 18 months. Started Jun 2026; status: recruiting.
02
Drugs
epcoritamabglofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07528352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07528352.